Esperion(ESPR) - 2025 Q1 - Quarterly Results

Exhibit 99.1 – Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – Esperion Reports First Quarter 2025 Financial Results – Expanded Development Portfolio with Introduction of Novel Program Targeting Primary Sclerosing Cholangitis (PSC) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., May 6, 2025 (GLOBE NEWSWIRE) – Esperion (NASDAQ: ESPR) today reported financial results for the first quarte ...